This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Aptinyx Inc. (N-methyl-D-aspartic acid (NMDA) receptor modulators for neurological disorders) raised $65mm in a Series A round led by New Leaf Venture Partners, which was joined by other new backers Frazier Healthcare Partners, Longitude Capital, and Osage University Partners; other participants included returning seed investors Adams Street Partners, LVP Life Science Ventures, PathoCapital, Goudy Park Capital, Beecken Petty O'Keefe & Co., and Northwestern University. New Leaf, Frazier, and Longitude added members to the board.
Drug Discovery Tools
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?